Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized...

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• The immune response to cancer is complex and influenced by various factors.
• Site-specific variations in anti-cancer immunity are not well understood.
• Tumor-infiltrating lymphocytes (TILs) play a critical role in cancer immunity.

Purpose of the Study:

• To investigate site-specific variations in immune cell infiltration and immune-regulatory molecule expression across ten cancer types.
• To identify common immune features and site-specific differences in the tumor microenvironment.
• To correlate immune profiles with cancer stage and gene expression related to antigen presentation.

Main Methods:

• Multiparametric analysis of immune cell subsets and immune-regulatory molecules in tumor samples from ten cancer types.
• Analysis of gene expression related to antigen presentation.
• Correlation of immune cell abundance and molecule expression with clinical parameters and cancer stage.

Main Results:

• Elevated infiltration of regulatory T cells was the most common feature across cancer types.
• Significant site-specific variations were observed in other lymphocyte subsets and immune-regulatory molecule expression on TILs.
• Similarities in immune profiles were noted between renal, liver, and lung cancers, and between lung and head and neck cancers.
• Co-expression of immune-inhibitory ligands was frequent in colorectal, lung, and ovarian cancers.
• Antigen presentation genes were dysregulated in liver and lung cancers.
• Co-inhibitory molecule expression on TILs increased with advanced cancer stage, while T-cell abundance correlated with enhanced antigen presentation gene expression.

Conclusions:

• Immune profiles in cancer exhibit significant site-specific heterogeneity.
• Understanding these variations is crucial for developing effective cancer immunotherapies.
• Cancer-specific or personalized immunotherapeutic strategies are needed to overcome resistance to immune-checkpoint inhibition.